Molecular mechanism of doxorubicin-induced cardiomyopathy - An update

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Doxorubicin is a widely used anti-neoplastic agent.
• Its clinical utility is significantly limited by dose-dependent cardiotoxicity.
• Cardiotoxicity affects the myocardium and other organs, impacting patient outcomes.

Purpose of the Study:

• To provide an updated review of the mechanisms underlying doxorubicin-induced cardiotoxicity and cardiomyopathies.
• To highlight recent findings and novel avenues for therapeutic interventions.
• To consolidate current knowledge on doxorubicin's detrimental effects on the heart.

Main Methods:

• Literature review of recent scientific findings on doxorubicin cardiotoxicity.
• Analysis of signaling pathways involved in doxorubicin-induced cardiac damage.
• Synthesis of information on emerging therapeutic strategies.

Main Results:

• Doxorubicin exerts its anti-cancer effect by DNA intercalation and topoisomerase 2 inhibition.
• Key mechanisms of cardiotoxicity include oxidative stress and cardiac mitochondrial damage.
• Other contributing factors identified are calcium dysregulation, endoplasmic reticulum stress, progenitor cell impairment, and immune system activation.

Conclusions:

• Understanding the multifaceted mechanisms of doxorubicin cardiotoxicity is crucial for developing effective interventions.
• Targeting pathways such as oxidative stress and calcium dysregulation may mitigate cardiac damage.
• Further research into novel pharmacotherapies is essential to improve the safety profile of doxorubicin treatment.